EGFR and colorectal carcinoma: In other words, RAS wild-type CRC patients progressing after oxaliplatin/capecitabine-based adjuvant chemotherapy developed more RAS mutations and resistance to anti-EGFR treatments than metastatic patients who did not receive adjuvant treatment.